The journal retracts the 2023 article cited above.
Following publication, the publisher identified concerns regarding the scope and peer review of this article. A subsequent investigation, which was conducted in accordance with Frontiers’ policies, found indicators of third-party involvement and inadequate peer review process. As the scientific integrity of the article cannot be guaranteed, and adhering to the recommendations of the Committee on Publication Ethics (COPE), the article is retracted.
The authors have not responded to this retraction.
This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers.
Summary
Keywords
Anlotinib, high-grade glioma, retrospective analysis, PFS, os
Citation
Frontiers Editorial Office (2024) Retraction: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: a retrospective analysis. Front. Oncol. 14:1383410. doi: 10.3389/fonc.2024.1383410
Received
07 February 2024
Accepted
09 February 2024
Published
20 February 2024
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
14 - 2024
Updates
Copyright
© 2024 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.